Anne Line Stensjøen1, Ole Solheim1, Kjell Arne Kvistad1, Asta K Håberg1, Øyvind Salvesen1, Erik Magnus Berntsen1. 1. Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (A.L.S, E.M.B.); Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway (O.S.); National Competence Centre for Ultrasound and Image Guided Therapy, St. Olavs University Hospital, Trondheim, Norway (O.S.); Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (O.S, A.K.H.); Department of Radiology, St. Olavs University Hospital, Trondheim, Norway (K.A.K, A.K.H., E.M.B.); Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway (Ø.S.).
Abstract
BACKGROUND: Glioblastomas are primary malignant brain tumors with a dismal prognosis. Knowledge of growth rates and underlying growth dynamics is useful for understanding basic tumor biology, developing realistic tumor models, and planning treatment logistics. METHODS: By using repeated pretreatment contrast-enhanced T1-weighted MRI scans from 106 patients (aged 26-83 years), we studied the growth dynamics of untreated glioblastomas in vivo. Growth rates were calculated as specific growth rates and equivalent volume doubling times. The fit of different possible growth models was assessed using maximum likelihood estimations. RESULTS: There were large variations in growth rates between patients. The median specific growth rate of the tumors was 1.4% per day, and the equivalent volume doubling time was 49.6 days. Exploring 3 different tumor growth models showed similar statistical fit for a Gompertzian growth model and a linear radial growth model and worse fit for an exponential growth model. However, large tumors had significantly lower growth rates than smaller tumors, supporting the assumption that glioblastomas reach a plateau phase and thus exhibit Gompertzian growth. CONCLUSION: Based on the fast growth rate of glioblastoma shown in this study, it is evident that poor treatment logistics will influence tumor size before surgery and can cause significant regrowth before adjuvant treatment. Since there is a known association between tumor volume, extent of surgical resection, and response to adjuvant therapy, it is likely that waiting times play a role in patient outcomes.
BACKGROUND:Glioblastomas are primary malignant brain tumors with a dismal prognosis. Knowledge of growth rates and underlying growth dynamics is useful for understanding basic tumor biology, developing realistic tumor models, and planning treatment logistics. METHODS: By using repeated pretreatment contrast-enhanced T1-weighted MRI scans from 106 patients (aged 26-83 years), we studied the growth dynamics of untreated glioblastomas in vivo. Growth rates were calculated as specific growth rates and equivalent volume doubling times. The fit of different possible growth models was assessed using maximum likelihood estimations. RESULTS: There were large variations in growth rates between patients. The median specific growth rate of the tumors was 1.4% per day, and the equivalent volume doubling time was 49.6 days. Exploring 3 different tumor growth models showed similar statistical fit for a Gompertzian growth model and a linear radial growth model and worse fit for an exponential growth model. However, large tumors had significantly lower growth rates than smaller tumors, supporting the assumption that glioblastomas reach a plateau phase and thus exhibit Gompertzian growth. CONCLUSION: Based on the fast growth rate of glioblastoma shown in this study, it is evident that poor treatment logistics will influence tumor size before surgery and can cause significant regrowth before adjuvant treatment. Since there is a known association between tumor volume, extent of surgical resection, and response to adjuvant therapy, it is likely that waiting times play a role in patient outcomes.
Authors: Christina H Wang; Jason K Rockhill; Maciej Mrugala; Danielle L Peacock; Albert Lai; Katy Jusenius; Joanna M Wardlaw; Timothy Cloughesy; Alexander M Spence; Russ Rockne; Ellsworth C Alvord; Kristin R Swanson Journal: Cancer Res Date: 2009-11-24 Impact factor: 12.701
Authors: Madison R Hansen; Edward Pan; Andrew Wilson; Morgan McCreary; Yeqi Wang; Thomas Stanley; Marco C Pinho; Xiaohu Guo; Darin T Okuda Journal: J Neurooncol Date: 2018-06-07 Impact factor: 4.130
Authors: Juan Jiménez-Sánchez; Álvaro Martínez-Rubio; Anton Popov; Julián Pérez-Beteta; Youness Azimzade; David Molina-García; Juan Belmonte-Beitia; Gabriel F Calvo; Víctor M Pérez-García Journal: PLoS Comput Biol Date: 2021-02-10 Impact factor: 4.475
Authors: Berdine L Heesterman; Lisa M H de Pont; Berit M Verbist; Andel G L van der Mey; Eleonora P M Corssmit; Frederik J Hes; Peter Paul G van Benthem; Jeroen C Jansen Journal: J Neurol Surg B Skull Base Date: 2017-07-31